Meningococcal Vaccines For Menomune And Bexsero Deep Research Available At Researchmoz.us

0

Researchmoz presents this most up-to-date research on'Meningococcal Vaccines For Menomune And Bexsero Deep Research Available At Researchmoz.us'.The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

http://www.researchmoz.us/menomune-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.
Menomune (Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined) is the brand name for Sanofi’s tetravalent polysaccharide vaccine sold in the US and Australia to protect against four N. meningitidis serogroups that cause meningococcal disease. Approved in the US in 1981 and Australia in 1994, Menomune was among the first available vaccines against meningococcal disease and was the standard of care in the US until the introduction of Menactra in 2005.

Bexsero (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

http://www.researchmoz.us/bexsero-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.
Bexsero (Meningococcal group B vaccine, rDNA, 4-component, adsorbed) is the brand name for Novartis’ four-component meningococcal vaccine that is indicated to protect children, adolescents, and adults two months of age and older against invasive infection caused by N. meningitidis serogroup B. Bexsero received EMA approval in January 2013 and is the first serogroup B vaccine to be marketed in the 5EU (EMA, 2012).
About Us:

ResearchMoz is the one stop online destination to find and buy market research reports. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets.

Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite: http://www.researchmoz.us/
Blog: http://globalandchinamarket.blogspot.com

Customer comments

No comments were found for Meningococcal Vaccines For Menomune And Bexsero Deep Research Available At Researchmoz.us. Be the first to comment!